Sanofi still swallowed Genzyme
It happened: Sanofi-aventis and Genzyme signed a takeover agreement
Pharmacy.ua based on Sanofi-aventis materialsOn February 16, 2011, Sanofi-aventis S.A. and Genzyme Corp. announced the conclusion of a final agreement.
Under the terms of the deal, Sanofi-aventis will acquire shares of Genzyme at $74 per share, the total amount of the transaction will be approximately $ 20.1 billion. In addition, an agreement was reached on the shareholders' right to a conditional premium to the agreed value of shares (Content Value Right), which will depend on the success in the development of the multiple sclerosis drug Lemtrada™ (alemtuzumab), as well as on the sales volumes of Cerezyme®/Cerezim® (imiglucerase) and Fabrazyme® (agalsidase) in twothousandeleven
The agreement was approved unanimously by the boards of directors of both companies. The transaction is expected to close at the beginning of Q2 2011. Representatives of Sanofi-aventis predict that due to the takeover of Genzyme by 2013, the company's net profit per share will increase by 0.75-1.003 euros.
Christopher A. Christopher A. Viehbacher, CEO of Sanofi-aventis, noted that the agreement with Genzyme is part of the company's long-term strategy and will create a favorable basis for the development of biotechnological research.
Henri A. Termeer The chairman of the Management Board of Genzyme added that this transaction will be a new stage for the company, and will also allow Genzyme and Sanofi-aventis to develop innovative technologies in therapy that will change the lives of patients with serious diseases for the better.
Portal "Eternal youth" http://vechnayamolodost.ru18.02.2011